Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Circulating tumor cells (CTCs) improve risk stratification according to the second revision of the international staging system (R2-ISS) and the ims-IMWG consensus genomic staging (CGS) in newly diagnosed multiple myeloma (NDMM): An analysis from the european CTC consortium.

View Full Paper
Ask AI
Bookmark
Share

Authors

DŽDavid ŽihalaGBGiuseppe BertugliaJKJonathan J. Keats

Discussion

Loading...

Member takes

Overview

Analysis reveals circulating tumor cells improve prognostic models for progression-free survival in multiple myeloma patients.

Key Points

  • Evaluate the clinical significance of circulating tumor cells in combination with R2-ISS and IMS-IMWG CGS in newly diagnosed multiple myeloma.
  • Collected patient-level data from 5 collaborative groups
  • Analyzed 1657 newly diagnosed multiple myeloma patients using flow cytometry for CTC enumeration
  • Assessed the impact of CTCs on risk stratification using R2-ISS and IMS-IMWG CGS
  • Conducted whole genome/exome sequencing on tumor cells to identify mutations
  • Circulating tumor cells were found as independent prognostic biomarkers for progression-free survival
  • CTC levels correlated with defined risk categories in both R2-ISS and IMS-IMWG cohorts
  • A prognostic model incorporating CTCs performed better than R2-ISS and CGS alone for predicting patient outcomes
  • Median progression-free survival varied significantly between patients with low vs high levels of CTCs

Cite This Study

Žihala et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e0dahttps://doi.org/10.1182/blood-2025-364
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1P01 | CIRCULATING TUMOR CELLS IMPROVE RISK STRATIFICATION ACCORDING TO THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM AND THE IMS-IMWG CONSENSUS GENOMIC STAGING IN NDMM PATIENTS. AN ANALYSIS FROM THE EUROPEAN CTC CONSORTIUM2026
  2. 2B04 | BLOOD-BASED RISK STRATIFICATION OF MYELOMA PATIENTS USING CIRCULATING TUMOR CELLS: RESULTS FROM THE EUROPEAN CTC CONSORTIUM2026
  3. 3P26 | CORRELATION OF THE CIRCULATING TUMOR CELLS AND R2-ISS SCORE IN NEWLY DIAGNOSED MYELOMA PATIENTS: RWE EXPERIENCE2026
  4. 4Low circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myeloma2024 · 12 citations
  5. 5Low circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myeloma2024 · 1 citations